Page 4 - Pharma Sector

Exporters want steel, pharmaceuticals sectors under RoDTEP scheme

The RoDTEP guidelines do not include sectors such as steel, organic & inorganic chemicals, and pharma under the scheme

Serum Institute buys 50% stake in pharma packaging firm Schott Kaisha

The joint venture is for pharmaceutical packaging

JB Chemicals & Pharmaceuticals posts Rs 119 crore profit April-June

Drug firm JB Chemicals & Pharmaceuticals on Thursday reported a consolidated net profit of Rs 119.05 crore for the quarter ended on June 30, 2021. The company had posted a net profit of Rs 119.50 crore for the corresponding period of the previous fiscal, JB Chemicals & Pharmaceuticals said in a filing to BSE. Consolidated revenue from operations of the company stood at Rs 606 crore for the quarter under consideration. It was Rs 522.3 crore for the same period a year ago, it added. "The organisation continues its strong performance well in the first quarter of the financial year. On the domestic front, we are one of the fastest growing companies in the industry," JBCPL CEO and Wholetime Director Nikhil Chopra said. While demand trends in international business continue to be volatile (given the COVID situation); the company's key markets like the US, South Africa have outperformed and even Russia/ CIS are seeing gradual signs of revival, he added. Shares of JB Chemicals & ..

Glenmark Life Sciences slips below issue price as stock falls 5%

On Friday, August 6, 2021, the company had made a quiet debut on the bourses as the shares listed at Rs 751.10 on the BSE

Windlas Biotech IPO oversubscribed 22.46 times on closing day

The initial public offer of Windlass Biotech, a manufacturer of pharmaceutical formulations, was subscribed 22.46 times on Friday, the closing day for subscription. The three-day IPO received bids for 13,77,39,750 shares against 61,36,252 shares on offer, as per NSE data. The category for Qualified Institutional Buyers(QIBs) was subscribed 24.40 times, non-institutional investors 15.73 times, and retail individual investors(RIIs) 24.27 times. The initial public offer had a fresh issue of up to Rs 165 crore and an offer for sale of up to 51,42,067 equity shares. The Rs 401.53-crore offer had a price range of Rs 448-460 per share. Windlas Biotech on Tuesday raised over Rs 120 crore from anchor investors. The proceeds from the IPO will be utilised for purchasing of equipment required for capacity expansion of the facility at Dehradun Plant-IV and addition of injectables dosage capability at the facility at Dehradun Plant-II. It will also be used for funding incremental working capi

Aurobindo Pharma channelising efforts to commercialise Covid-19 vaccine

The Hyderabad-based drug major is looking to develop products with higher complexity, focus on injectables business and expand business in high growth markets like China.

Ind Swift Labs tanks 16% on selling API business to PI Industries

PI Ind said the purchase consideration of Rs 1,530 crore will be paid in all-cash and funded from the proceeds of the completed QIP and internal accruals

Sun Pharma posts consolidated net profit of Rs 1,444 crore in Q1

The company had posted a net loss of Rs 1,655.60 crore for the corresponding period of the previous fiscal

Sun Pharma rallies 9%, hits over 4-year high on strong June quarter results

The management said Sun Pharma witnessed a strong Q1, driven by a combination of robust core business growth, low base and some sale of Covid products

Windlas Biotech IPO to open on Aug 4; price band set at Rs 448-460/share

Windlas Biotech, manufacturer of pharmaceutical formulations, on Thursday said it has fixed a price band of Rs 448-460 a share for its initial share-sale. The three-day initial public offer (IPO) will open on August 4 and conclude on August 6, the company announced in a virtual press conference. The IPO comprises fresh issuance of equity shares worth Rs 165 crore and and an offer for sale of up to 5,142,067 equity shares. As a part of the OFS, Vimla Windlass will offload 11.36 lakh equity shares, and investor Tano India Private Equity Fund II will sell 40,06,067 equity shares. At the upper end of the price band, the initial share-sale will fetch Rs 401.53 crore. The proceeds from the IPO will be utilised for purchasing of equipment required for capacity expansion of the facility at Dehradun Plant -IV and addition of injectables dosage capability at the facility at Dehradun Plant-II. It will also be used for funding incremental working capital requirements, repayment/ prepayment o

Pharma PLI scheme has export generation potential of Rs 1.96 tn: Mandaviya

PLI for pharmaceutical products has export generation potential of Rs 1,96,000 crore over a period of six years, Parliament was informed on Tuesday.

Sanofi India reports second quarter net profit at Rs 178.3 crore

Revenue from operations of the company stood at Rs 789.1 crore for the quarter under consideration

Dr Reddy's slips over 10% post June quarter results, anonymous complaint

Gross profit margin decreased by 380 bps over the previous year and 150 bps sequentially, majorly on account of price erosion and increase in inventory provisions related to few products

Alembic Pharma dips 8% on disappointing June quarter results

Ebitda (earnings before interest, taxes, depreciation, and amortization) margins declined 1258 basis points (bps) YoY to 17.8 per cent, due to higher other expenditure

Caplin Point jumps 19%, hits record high; stock soars 37% in seven days

A combined 5.8 million equity shares, representing 7.6 per cent of the total equity of Caplin Point Laboratories, had changed hands on NSE and BSE till 12:56 pm

Indian pharma industry to touch $130 bn by 2030: Dr Reddy's chairman

The Indian pharmaceutical industry is expected to grow almost by three times to about 130 billion US dollars by 2030

Glenmark Life Sciences to invest Rs 600 cr to double capacity in four years

Glenmark Life Sciences is the arm of drug major Glenmark Pharmaceuticals.

Gland Pharma rallies 8% on strong revenue growth in June quarter

Gland Pharma said the growth in revenue was contributed from a mix of launch of new products and volume growth in existing products

Gland Pharma Q1 consolidated net profit up 12% to Rs 350.7 crore

Drug firm Gland Pharma on Wednesday reported an 11.83 percent increase in its consolidated net profit to Rs 350.7 crore for the quarter ended June 30, 2021, on account of robust sales in all markets.

Pharma shares in focus; Alkem, Divi's Lab, Syngene hit record highs

Thus far in the financial year 2021-22 (FY22), the S&P BSE Healthcare index has rallied 24 per cent, as against 9 per cent gain in the S&P BSE Sensex